AngioDynamics (NASDAQ:ANGO) Issues FY 2026 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of -0.330–0.230 for the period, compared to the consensus earnings per share estimate of -0.310. The company issued revenue guidance of $312.0 million-$314.0 million, compared to the consensus revenue estimate of $310.1 million.

AngioDynamics Stock Up 4.3%

Shares of ANGO stock opened at $13.23 on Tuesday. AngioDynamics has a 12-month low of $8.27 and a 12-month high of $13.99. The firm has a fifty day moving average of $12.69 and a 200-day moving average of $11.00. The firm has a market capitalization of $545.08 million, a price-to-earnings ratio of -16.96 and a beta of 0.47.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on ANGO shares. Wall Street Zen lowered AngioDynamics from a “buy” rating to a “hold” rating in a research report on Sunday, December 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a research note on Wednesday, October 8th. Finally, Canaccord Genuity Group raised their target price on shares of AngioDynamics from $17.00 to $18.00 and gave the stock a “buy” rating in a report on Friday, October 3rd. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $19.33.

Insider Transactions at AngioDynamics

In other AngioDynamics news, SVP Lawrence T. Weiss purchased 10,000 shares of the firm’s stock in a transaction dated Tuesday, October 21st. The stock was bought at an average cost of $11.81 per share, with a total value of $118,100.00. Following the purchase, the senior vice president directly owned 93,597 shares of the company’s stock, valued at $1,105,380.57. The trade was a 11.96% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO James C. Clemmer acquired 10,000 shares of the business’s stock in a transaction dated Thursday, October 9th. The stock was acquired at an average cost of $11.15 per share, for a total transaction of $111,500.00. Following the transaction, the chief executive officer owned 882,529 shares of the company’s stock, valued at $9,840,198.35. This represents a 1.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have purchased 20,890 shares of company stock valued at $239,532. 6.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On AngioDynamics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. State of Wyoming bought a new position in shares of AngioDynamics in the 2nd quarter valued at about $31,000. Russell Investments Group Ltd. boosted its position in AngioDynamics by 329.5% during the third quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 3,213 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in AngioDynamics by 359.0% during the second quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier’s stock valued at $54,000 after purchasing an additional 4,268 shares during the last quarter. BNP Paribas Financial Markets grew its stake in AngioDynamics by 106.0% in the third quarter. BNP Paribas Financial Markets now owns 7,473 shares of the medical instruments supplier’s stock valued at $83,000 after purchasing an additional 3,846 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of AngioDynamics during the 2nd quarter worth approximately $90,000. 89.43% of the stock is owned by institutional investors.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.